Healthcare Industry News: dilatation catheter
News Release - April 7, 2008
OrbusNeich Receives CE Mark Approval for Sapphire(TM) 1.25MM PTCA Dilatation CatheterSmall-Diameter Balloon Catheter Designed for Pre-Dilatation of Tight, Calcified CTO Lesions That Require Best Crossability
HONG KONG, April 7 (HSMN NewsFeed) -- OrbusNeich today announced that it has received CE Mark approval for the Sapphire(TM) 1.25mm PTCA dilatation catheter.
"The Sapphire 1.25mm balloon is easily deliverable with good pushability, and may be considered a first choice in highly stenotic lesions," said Professor Tan Huay Cheem of the University Hospital in Singapore.
OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.
A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.
Web site: http://www.OrbusNeich.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.